{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:11:57Z","timestamp":1790230317333,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>Evaluate control rates of IGABT combined with CCRT for the treatment of locally advanced cervical cancer. Describe survival outcomes in patients treated with IGABT combined with CCRT for locally advanced cervical cancer. Describe toxicities in patients treated with IGABT combined with CCRT for locally advanced cervical cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Purpose.<\/jats:title>\n                  <jats:p>To evaluate the outcomes of patients with locally advanced cervical cancer treated with three-dimensional image-guided brachytherapy (IGABT) after concomitant chemoradiation (CCRT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods.<\/jats:title>\n                  <jats:p>Data from patients treated with CCRT followed by magnetic resonance imaging-guided or computed tomography-guided pulsed-dose-rate brachytherapy, performed according to the Groupe Europ\u00e9en de Curieth\u00e9rapie\u2013European Society for Radiotherapy and Oncology guidelines, were reviewed. At first, stage I or II patients systematically underwent radical hysterectomy or were offered a randomized study evaluating hysterectomy. Then, hysterectomy was limited to salvage treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Of 163 patients identified, 27% had stage IB, 57% had stage II, 12% had stage III, and 3% had stage IVA disease. The mean dose delivered (in 2-Gy dose equivalents) to 90% of the high-risk clinical target volume was 78.1 \u00b1 9.6 Gy, whereas the doses delivered to organs at risk were maintained under the usual thresholds. Sixty-one patients underwent a hysterectomy. Macroscopic residual disease was found in 13 cases. With a median follow-up of 36 months (range, 5\u201379 months), 45 patients had relapsed. The 3-year overall survival rate was 76%. Local and pelvic control rates were 92% and 86%, respectively. According to the Common Toxicity Criteria 3.0, 7.4% of patients experienced late grade 3 or 4 toxicity. Most of those had undergone postradiation radical surgery (2.9% vs. 14.8; p = .005).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>IGABT combined with CCRT provides excellent locoregional control rates with low treatment-related morbidity, justifying the elimination of hysterectomy in the absence of obvious residual disease. Distant metastasis remains an important first relapse and may warrant more aggressive systemic treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2012-0367","type":"journal-article","created":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T02:11:16Z","timestamp":1365473476000},"page":"415-422","source":"Crossref","is-referenced-by-count":71,"title":["Adaptive 3D Image-Guided Brachytherapy: A Strong Argument in the Debate on Systematic Radical Hysterectomy for Locally Advanced Cervical Cancer"],"prefix":"10.1093","volume":"18","author":[{"given":"Renaud","family":"Mazeron","sequence":"first","affiliation":[{"name":"a Departments of Radiation Oncology, Institut de Canc\u00e9rologie Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gilmore","sequence":"additional","affiliation":[{"name":"a Departments of Radiation Oncology, Institut de Canc\u00e9rologie Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Dumas","sequence":"additional","affiliation":[{"name":"b Departments of Medical Physics, Institut de Canc\u00e9rologie Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Champoudry","sequence":"additional","affiliation":[{"name":"b Departments of Medical Physics, Institut de Canc\u00e9rologie Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Goulart","sequence":"additional","affiliation":[{"name":"a Departments of Radiation Oncology, Institut de Canc\u00e9rologie Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Vanneste","sequence":"additional","affiliation":[{"name":"a Departments of Radiation Oncology, Institut de Canc\u00e9rologie Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tailleur","sequence":"additional","affiliation":[{"name":"a Departments of Radiation Oncology, Institut de Canc\u00e9rologie Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Morice","sequence":"additional","affiliation":[{"name":"c Departments of Surgery, Institut de Canc\u00e9rologie Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Haie-Meder","sequence":"additional","affiliation":[{"name":"a Departments of Radiation Oncology, Institut de Canc\u00e9rologie Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,4,8]]},"reference":[{"issue":"suppl 5","key":"2021122308261804700_B1","doi-asserted-by":"crossref","first-page":"v37","DOI":"10.1093\/annonc\/mdq162","article-title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Haie-Meder","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122308261804700_B2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.radonc.2004.12.015","article-title":"Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): Concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV","volume":"74","author":"Haie-Meder","year":"2005","journal-title":"Radiother Oncol"},{"key":"2021122308261804700_B3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1634\/theoncologist.2011-0007","article-title":"Analysis of morbidity and clinical implications of laparoscopic para-aortic lymphadenectomy in a continuous series of 98 patients with advanced-stage cervical cancer and negative PET-CT imaging in the para-aortic area","volume":"16","author":"Uzan","year":"2011","journal-title":"The Oncologist"},{"key":"2021122308261804700_B4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.canrad.2008.04.002","article-title":"[Brachytherapy at the Institut Gustave-Roussy: Personalized vaginal mould applicator: Technical modification and improvement]","volume":"12","author":"Albano","year":"2008","journal-title":"Cancer Radiother"},{"key":"2021122308261804700_B5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.brachy.2009.08.014","article-title":"Technical aspects and perspectives of the vaginal mold applicator for brachytherapy of gynecologic malignancies","volume":"9","author":"Magn\u00e9","year":"2010","journal-title":"Brachytherapy"},{"key":"2021122308261804700_B6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1634\/theoncologist.2011-0276","article-title":"Results of the GYNECO 02 study, an FNCLCC phase III trial comparing hysterectomy with no hysterectomy in patients with a (clinical and radiological) complete response after chemoradiation therapy for stage IB2 or II cervical cancer","volume":"17","author":"Morice","year":"2012","journal-title":"The Oncologist"},{"key":"2021122308261804700_B7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.radonc.2005.11.014","article-title":"Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology","volume":"78","author":"P\u00f6tter","year":"2006","journal-title":"Radiother Oncol"},{"key":"2021122308261804700_B8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0090-8258(03)00173-2","article-title":"Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: A randomized trial of the Gynecologic Oncology Group","volume":"89","author":"Keys","year":"2003","journal-title":"Gynecol Oncol"},{"key":"2021122308261804700_B9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.semradonc.2009.11.006","article-title":"Adaptive management of cervical cancer radiotherapy","volume":"20","author":"Tanderup","year":"2010","journal-title":"Semin Radiat Oncol"},{"key":"2021122308261804700_B10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ygyno.2006.01.022","article-title":"Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: Morbidity and outcome: Results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer)","volume":"102","author":"Classe","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"suppl 1","key":"2021122308261804700_B11","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.ygyno.2007.07.015","article-title":"The role of surgery after chemoradiation therapy and brachytherapy for stage IB2\/II cervical cancer","volume":"107","author":"Morice","year":"2007","journal-title":"Gynecol Oncol"},{"key":"2021122308261804700_B12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1245\/ASO.2005.05.020","article-title":"Results of hysterectomy in patients with bulky residual disease at the end of chemoradiotherapy for stage IB2\/II cervical carcinoma","volume":"12","author":"Azria","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"2021122308261804700_B13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.radonc.2011.07.012","article-title":"Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer","volume":"100","author":"P\u00f6tter","year":"2011","journal-title":"Radiother Oncol"},{"key":"2021122308261804700_B14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijrobp.2008.06.1912","article-title":"Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients","volume":"74","author":"Chargari","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308261804700_B15","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/IGC.0b013e31821caa55","article-title":"Reporting and validation of gynaecological Groupe Europeen de Curietherapie European Society for Therapeutic Radiology and Oncology (ESTRO) brachytherapy recommendations for MR image-based dose volume parameters and clinical outcome with high dose-rate brachytherapy in cervical cancers: A single-institution initial experience","volume":"21","author":"Mahantshetty","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"2021122308261804700_B16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.radonc.2007.04.012","article-title":"Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer","volume":"83","author":"P\u00f6tter","year":"2007","journal-title":"Radiother Oncol"},{"key":"2021122308261804700_B17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.radonc.2012.04.007","article-title":"Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: Results of the French STIC prospective study","volume":"103","author":"Charra-Brunaud","year":"2012","journal-title":"Radiother Oncol"},{"key":"2021122308261804700_B18","volume-title":"Participants","author":"Retro"},{"key":"2021122308261804700_B19","author":"EMBRACE"},{"key":"2021122308261804700_B20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(01)05965-7","article-title":"Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis","volume":"358","author":"Green","year":"2001","journal-title":"Lancet"},{"key":"2021122308261804700_B21","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2009.25.9663","article-title":"Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix","volume":"29","author":"Due\u00f1as-Gonz\u00e1lez","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308261804700_B22","volume-title":"Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer"},{"key":"2021122308261804700_B23","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/sj.onc.1205006","article-title":"Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers","volume":"21","author":"Abdulkarim","year":"2002","journal-title":"Oncogene"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2012-0367","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0367","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/4\/415\/41856052\/oncolo_18_4_415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/4\/415\/41856052\/oncolo_18_4_415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T22:50:45Z","timestamp":1640299845000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/4\/415\/6398721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,1]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,8]]},"published-print":{"date-parts":[[2013,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0367","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,4,1]]},"published":{"date-parts":[[2013,4,1]]}}}